Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells

Toxicology and Applied Pharmacology

Volumn 241, Issue 1, 2009, Pages 23-35

  Schildknecht, Stefan ^a   Pöltl, Dominik ^a   Nagel, Daniel M ^a   Matt, Florian ^a   Scholz, Diana ^a   Lotharius, Julie ^a   Schmieg, Nathalie ^a   Salvo Vargas, Alberto ^a   Leist, Marcel ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Dopamine; LUHMES; Mitochondria; MPP+; Neurotoxicity; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; DOPAMINE TRANSPORTER; GLUTATHIONE; IODOTYROSINE; METIROSINE;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONCENTRATION PROCESS; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; LIPID PEROXIDATION; NERVE CELL DEGENERATION; NEURITE; NEUROTOXICITY; NONHUMAN; PHENOTYPE; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; CELL DEATH; CELLS, CULTURED; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HUMANS; LIPID PEROXIDATION; MESENCEPHALON; METHYLTYROSINES; MITOCHONDRIA; MONOIODOTYROSINE; MPTP POISONING; NEURITES; NEURONS; TIME FACTORS;

EID: 70350031056     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.07.027     Document Type: Article

References (57)

1. Berg D., and Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov. Disord. 21 (2006) 1299-1310
2. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
3. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., and Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155 (1999) 268-273
4. Boll J.B., Geist M.A., Kaminski Schierle G.S., Petersen K., Leist M., and Vaudano E. Improvement of embryonic dopaminergic neurone survival in culture and after grafting into the striatum of hemiparkinsonian rats by CEP-1347. J. Neurochem. 88 (2004) 698-707
5. Carrasco E., and Werner P. Selective destruction of dopaminergic neurons by low concentrations of 6-OHDA and MPP+: protection by acetylsalicylic acid aspirin. Parkinsonism. Relat. Disord. 8 (2002) 407-411
6. Choi W.S., Kruse S.E., Palmiter R.D., and Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 15136-15141
7. Di Monte D., Ekstrom G., Shinka T., Smith M.T., Trevor A.J., and Castagnoli Jr. N. Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes. Chem. Biol. Interact. 62 (1987) 105-116
8. Dringen R., Kussmaul L., Gutterer J.M., Hirrlinger J., and Hamprecht B. The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells. J. Neurochem. 72 (1999) 2523-2530
9. Fountaine T.M., Venda L.L., Warrick N., Christian H.C., Brundin P., Channon K.M., and Wade-Martins R. The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur. J. Neurosci. 28 (2008) 2459-2473
10. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., and Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70 5 (1998) 1973-1978
11. Gartlon J., Kinsner A., Bal-Price A., Coecke S., and Clothier R.H. Evaluation of a proposed in vitro test strategy using neuronal and non-neuronal cell systems for detecting neurotoxicity. Toxicol. In. Vitro. 20 (2006) 1569-1581
12. Grimsby J., Toth M., Chen K., Kumazawa T., Klaidman L., Adams J.D., Karoum F., Gal J., and Shih J.C. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat. Genet. 17 (1997) 206-210
13. Guillot T.S., and Miller G.W. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 39 2 (2009) 149-170
14. Hald A., Van Beek J., and Lotharius J. Inflammation in Parkinson's disease: causative or epiphenomenal?. Subcell. Biochem. 42 (2007) 249-279
15. Hasbani D.M., Perez F.A., Palmiter R.D., and O'Malley K.L. Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in vivo. J. Neurosci. 25 (2005) 9428-9433
16. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984) 467-469
17. Jakowec M.W., and Petzinger G.M. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp. Med. 54 (2004) 497-513
18. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 2173-2177
19. Kaneko M., Saito Y., Saito H., Matsumoto T., Matsuda Y., Vaught J.L., Dionne C.A., Angeles T.S., Glicksman M.A., Neff N.T., Rotella D.P., Kauer J.C., Mallamo J.P., Hudkins R.L., and Murakata C. Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. J. Med. Chem. 40 (1997) 1863-1869
20. Kitayama S., Shimada S., and Uhl G.R. Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann. Neurol. 32 (1992) 109-111
21. Kitayama S., Morita K., and Dohi T. Uptake and release of dopamine through the rat dopamine transporter expressed in Xenopus laevis oocyte: evaluation by voltammetric measurement of intracellular dopamine concentration. Neurosci. Lett. 211 (1996) 132-134
22. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
23. Langston J.W., Irwin I., Langston E.B., and Forno L.S. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett. 48 (1984) 87-92
24. Leist M., Volbracht C., Fava E., and Nicotera P. 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. Mol. Pharmacol. 54 (1998) 789-801
25. Litvan I., Chesselet M.F., Gasser T., Di Monte D.A., Parker Jr. D., Hagg T., Hardy J., Jenner P., Myers R.H., Price D., Hallett M., Langston W.J., Lang A.E., Halliday G., Rocca W., Duyckaerts C., Dickson D.W., Ben-Shlomo Y., Goetz C.G., and Melamed E. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J. Neuropathol. Exp. Neurol. 66 (2007) 329-336
26. Litvan I., Halliday G., Hallett M., Goetz C.G., Rocca W., Duyckaerts C., Ben-Shlomo Y., Dickson D.W., Lang A.E., Chesselet M.F., Langston W.J., Di Monte D.A., Gasser T., Hagg T., Hardy J., Jenner P., Melamed E., Myers R.H., Parker Jr. D., and Price D.L. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J. Neuropathol. Exp. Neurol. 66 (2007) 251-257
27. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3 (2002) 932-942
28. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275 (2000) 38581-38588
29. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., and Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277 (2002) 38884-38894
30. Lotharius J., Falsig J., van Beek J., Payne S., Dringen R., Brundin P., and Leist M. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci. 25 (2005) 6329-6342
31. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., and Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311 (1984) 464-467
32. Meissner W., Prunier C., Guilloteau D., Chalon S., Gross C.E., and Bezard E. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol. Neurobiol. 28 (2003) 209-218
33. Mizuno Y., Suzuki K., Sone N., and Saitoh T. Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains. Neurosci. Lett. 81 (1987) 204-208
34. Mizuno Y., Sone N., Suzuki K., and Saitoh T. Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain. J. Neurol. Sci. 86 (1988) 97-110
35. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J. Neural. Transm. 109 (2002) 1159-1180
36. Paul G., Christophersen N.S., Raymon H., Kiaer C., Smith R., and Brundin P. Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line-studies in vitro and after intracerebral grafting in vivo. Mol. Cell. Neurosci. 34 (2007) 390-399
37. Pifl C., Giros B., and Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 13 (1993) 4246-4253
38. Pileblad E., and Carlsson A. Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain. Neuropharmacology 24 (1985) 689-692
39. PRECEPT. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69 (2007) 1480-1490
40. Ramsay R.R., and Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261 (1986) 7585-7587
41. Ramsay R.R., Krueger M.J., Youngster S.K., Gluck M.R., Casida J.E., and Singer T.P. Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 56 (1991) 1184-1190
42. Richardson J.R., Caudle W.M., Guillot T.S., Watson J.L., Nakamaru-Ogiso E., Seo B.B., Sherer T.B., Greenamyre J.T., Yagi T., Matsuno-Yagi A., and Miller G.W. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol. Sci. 95 (2007) 196-204
43. Saporito M.S., Brown E.M., Miller M.S., and Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288 (1999) 421-427
44. Singer T.P., Ramsay R.R., McKeown K., Trevor A., and Castagnoli Jr. N.E. Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology 49 (1988) 17-23
45. Sirinathsinghji D.J., Heavens R.P., and McBride C.S. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions. Brain Res. 443 (1988) 101-116
46. Sonsalla P.K., Albers D.S., and Zeevalk G.D. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 14 (1998) 69-74
47. Staal R.G., and Sonsalla P.K. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J. Pharmacol. Exp. Ther. 293 (2000) 336-342
48. Staal R.G., Hogan K.A., Liang C.L., German D.C., and Sonsalla P.K. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 293 (2000) 329-335
49. Stokes A.H., Hastings T.G., and Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55 (1999) 659-665
50. Sulzer D., St Remy C., and Rayport S. Reserpine inhibits amphetamine action in ventral midbrain culture. Mol. Pharmacol. 49 (1996) 338-342
51. Thomas B., and Beal M.F. Parkinson's disease. Hum. Mol. Genet. 16 (2007) R183-R194 Spec No. 2
52. Vergo S., Johansen J.L., Leist M., and Lotharius J. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res. 1185 (2007) 18-32
53. Volbracht C., van Beek J., Zhu C., Blomgren K., and Leist M. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur. J. Neurosci. 23 (2006) 2611-2622
54. Wu E.Y., Smith M.T., Bellomo G., and Di Monte D. Relationships between the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes. Arch. Biochem. Biophys. 282 (1990) 358-362
55. Wullner U., Loschmann P.A., Schulz J.B., Schmid A., Dringen R., Eblen F., Turski L., and Klockgether T. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. Neuroreport 7 (1996) 921-923
56. Zhou C., Huang Y., and Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci. 1147 (2008) 93-104
57. Zhu J.H., Horbinski C., Guo F., Watkins S., Uchiyama Y., and Chu C.T. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am. J. Pathol. 170 (2007) 75-86